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Background: Buprenorphine is an effective treatment for opioid dependence that can be provided in a primary
care setting. Offering this treatment may also facilitate the identification and treatment of other chronic medical
conditions.
Methods: We retrospectively reviewed the medical records of 168 patients who presented to a primary care clinic
for treatment of opioid dependence and who received a prescription for sublingual buprenorphine within a month
of their initial visit.
Results: Of the 168 new patients, 122 (73%) did not report having an established primary care provider at the time
of the initial visit. One hundred and twenty-five patients (74%) reported at least one established chronic condition
at the initial visit. Of the 215 established diagnoses documented on the initial visit, 146 (68%) were not being
actively treated; treatment was initiated for 70 (48%) of these within one year. At least one new chronic medical
condition was identified in 47 patients (28%) during the first four months of their care. Treatment was initiated for
39 of the 54 new diagnoses (72%) within the first year.
Conclusions: Offering treatment for opioid dependence with buprenorphine in a primary care practice is
associated with the identification and treatment of other chronic medical conditions.Background
Opioid and other drug dependence are chronic medical
conditions, which can be treated in an outpatient pri-
mary care setting as other illnesses are [1]. A number of
studies have demonstrated the safety and efficacy of
office-based treatment of opioid dependence with sub-
lingual formulations of buprenorphine [2-6]. Potential
advantages of office-based treatment over traditional
methadone programs include feasibility of implementa-
tion in outpatient practices [7]; recruitment of patients
who have been reticent to join methadone programs due
to expense, need for more frequent attendance, and
associated stigma [8]; improved patient retention in
treatment [9-11]; and increased patient satisfaction [12].
Individuals with drug dependence have a high burden
of medical and psychiatric illness [13-15]. Integration of* Correspondence: theresa.rowe@yale.edu
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reproduction in any medium, provided the ordrug treatment and primary care services may also facili-
tate the identification and treatment of other chronic
medical conditions. Previous studies have shown that
providing on-site medical care with drug treatment is
associated with improved follow-up with care [16],
improved drug outcomes [17,18], and a reduction in
emergency department use and hospitalization [19,20].
However, there have been few studies of the medical care
of patients engaged in office-based buprenorphine treat-
ment. We undertook this study to evaluate the identifica-
tion and treatment of other chronic medical conditions
among patients who initiated office-based buprenorphine
treatment in an academic primary care practice.
Methods
Comprehensive Care Practice is a primary care practice
on the campus of The Johns Hopkins Bayview Medical
Center in Baltimore, Maryland, USA (an academic hos-
pital center). The practice is staffed by five attending
physicians who are certified to prescribe buprenorphine,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic information at initial visit
Characteristic Number (total = 168)












Injection drug use (ever) 91 (54%)
Drugs used
Heroin 134 (80%)
Prescription opioids 60 (36%)
Cocaine 92 (55%)
Established primary care physician at initial visit 46 (27%)
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and a nurse practitioner. All of the practitioners provide
primary care, with a concentration on caring for patients
with substance use disorders and HIV infection. It is the
policy of the practice that buprenorphine treatment is
provided as part of primary care, and buprenorphine is
only prescribed to patients who also receive their primary
care at this practice.
A cohort of 255 patients who had been given at least one
prescription for sublingual buprenorphine from August
2003 until September 2007 had been previously identi-
fied, and their drug treatment outcomes have been
reported [21]. For this study, we included the subset of
patients who had requested treatment for opioid depend-
ence on their initial visit at the practice and had been
prescribed the sublingual formulation of buprenorphine
or buprenorphine/naloxone within a month of their
initial visit.
Data were collected retrospectively from the patient
medical records. Both paper charts and electronic medical
chart were reviewed, and a data abstraction instrument
was used to standardize data collection. Demographic in-
formation recorded included age, gender, and type of in-
surance. The standard initial history and physical form
used by this practice includes a page on drug and alcohol
use history, prior injection drug use, addiction treatment,
and complications of drug and alcohol use. Substance use
history collected included substances used and past/
current injection drug use. We also recorded known
chronic medical conditions that patients reported at the
time of the initial visit and were documented in the his-
tory and at the physical. In addition, we recorded any in-
formation documented regarding treatment of these
known medical conditions, including active medication
lists and current specialty care. Patients are routinely
asked if they have a current or recent primary care pro-
vider, and records are requested at the initial visit. We
recorded whether patients reported an established rela-
tionship with a primary care provider at the time of their
initial visit. We reviewed records from the first four
months after the initial visit to record any chronic medical
conditions that were identified during this period and
reviewed records for up to a year to see if any treatment
was initiated for these problems. Treatment included
counseling (if documented in the patient’s chart), pre-
scribed medication, or referrals for specialty care. All chart
reviews were performed by the first author (TAR); when
there were questions about classification, these were
reviewed with the senior author (DAR), and decisions
were made by consensus.
Data analysis was primarily descriptive; we used chi-
squared analysis to compare the identification of new
medical problems among those who had an established
primary care provider at the initial visit with those whodid not. This study was approved by the institutional re-
view board of Johns Hopkins University.
Results
One hundred eighty-nine new patients had come to the
practice to receive treatment for opioid dependence and
received a prescription for buprenorphine within a
month of their initial visit. Of these, 168 (88.9%) patient
charts were reviewed; 21 charts were not reviewed due
to gaps in identification of subjects or incomplete or in-
accessible medical records. Table 1 provides demo-
graphic data on the cohort. The mean age was 40
(range, 20 to 64 years). About half (52%) had commer-
cial insurance at their initial visit; 26% had Medicaid,
23% had Medicare, and 3% had no insurance. Fifty-three
percent were employed, 24% were unemployed, and 23%
were disabled. Over half the patients (54%) reported past
injection drug use. Eighty percent reported using heroin,
and 36% reported using prescription opioids (16%
reported using both); 55% reported cocaine use. Forty-six
patients (27%) identified an established primary care pro-
vider at the time of their initial visit.
At least one new chronic medical condition was iden-
tified in 47 patients (28%) during the first four months
of care. Table 2 provides data on the new diagnoses. A
total of 54 new diagnoses were identified; the most com-
mon were hypertension (n = 15), hepatitis C (n = 12),
hyperlipidemia (n = 10), psychiatric disorders (n = 9),
and diabetes mellitus (n = 3). Treatment was initiated
for 39 of these new diagnoses (72%) within the first year.





Receiving Treatment at Initial Visit
(% of established diagnoses)
Treatment Initiated: new and
established diagnoses (%)
Psychiatric 78 (46%) 9 (5%) 33 (20%) 44 (77%)
Hepatitis C 62 (37%) 12 (7%) 0 (0%) 2 (3%)
Hypertension 28 (17%) 15 (9%) 10 (36%) 32 (76%)
Hyperlipidemia 9 (5%) 10 (6%) 4 (44%) 14 (74%)
HIV 7 (4%) 0 (0%) 1 (14%) 2 (29%)
Diabetes 4 (2%) 3 (2%) 2 (50%) 5 (71%)
Other 27 (16%) 5 (3%) 19 (11%) 11 (34%)
Total 215 (74%*) 54 (28%*) 69 (32%) 110 (41%)
*Percentage with one or more diagnoses.
Rowe et al. Addiction Science & Clinical Practice 2012, 7:22 Page 3 of 5
http://www.ascpjournal.org/content/7/1/22Twenty new diagnoses were treated with prescription
medications, and two subjects received specialty refer-
rals. Of the 46 subjects who reported having a primary
care provider at their initial visit, 15 (32.6%) had a new
diagnosis in the first four months compared with 32
(26.2%) of the 122 subjects who did not; this difference
was not significant (p = 0.44).
One-hundred twenty-five subjects (66%) had at least
one chronic medical condition identified at the first visit.
Table 2 provides data on the previously identified
chronic medical conditions and whether the patient was
on treatment at the initial visit. A total of 215 estab-
lished diagnoses were documented on the initial visit, of
which 146 (68%) were not being actively treated at that
time. The most common diagnoses were psychiatric disor-
ders (n = 78), hepatitis C (n = 62), hypertension (n = 28),
hyperlipidemia (n = 9), and HIV infection (n = 7). Seventy
of the previously untreated established diseases (43%)
were treated within one year.
Overall, as shown in Table 2, treatment was initiated
for 110 (41%) of the established or newly diagnosed con-
ditions. Although only 69 (32%) of the 215 previously
identified conditions were being actively treated at the
time of initial presentation, by the end of the first year
after initiation of office-based buprenorphine treatment,
168 (66%) of the 269 established or newly diagnosed
conditions had been addressed with counseling, medical
treatment, or referral to specialty care.
Discussion
Office-based buprenorphine treatment has been shown
to be safe and effective for treatment of opioid depend-
ence and allows for integration of treatment into the pri-
mary care setting [2-4]. Our own experience with
treating patients has likewise been positive in terms of
drug treatment outcomes [21]. This study adds to our
previous findings by illustrating how treatment of opioid
dependence in a primary care setting offers the additional
benefit of facilitating the identification and treatment ofother chronic medical conditions. Two-thirds of the
patients presenting to this practice for treatment of opioid
dependence had at least one other known chronic medical
condition documented at presentation, and at least one
new chronic medical condition was diagnosed in more
than a quarter of the subjects. Most did not report an
established source for primary care. If these patients had
sought treatment at a drug treatment program that did
not also provide primary care, these medical conditions
might not have been identified. In addition to identifica-
tion of chronic medical conditions, we found that most
patients received some form of treatment for their previ-
ously identified or newly diagnosed conditions, suggesting
that treatment of drug dependence in the primary care
setting engages patients in longitudinal care and facilitates
the ongoing management of other chronic medical pro-
blems. Providing buprenorphine treatment in a primary
care setting is congruent with the move toward the
patient-centered medical home model and has the poten-
tial for engaging and improving the health of a vulnerable
and historically underserved population.
There are few studies looking at the treatment of other
chronic medical conditions among patients receiving
office-based buprenorphine. One study of a cohort of 228
patients beginning buprenorphine treatment reported that
most had medical or psychiatric comorbidities that were
being co-managed along with their addiction treatment
[22]. Most of the attention to date has been paid to inte-
grating office-based buprenorphine with the treatment of
HIV infection with antiretroviral therapy (ART) [23,24]. A
recent study by Altice and colleagues [25] found that initi-
ating buprenorphine in an HIV clinical care setting was
associated with initiation of ART and improved CD4
lymphocyte counts. Previous studies with methadone main-
tenance subjects have found that providing on-site medical
care resulted in improved follow-up with medical care [16]
and reduced use of acute health care services [26]. Further
research is needed to look at the effect on clinical outcomes
and to determine optimal models of care.
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relied on chart review and documentation by the clini-
cians, who themselves relied on patient reports. It is pos-
sible that some of these problems had been previously
identified and treated, but these were not reported by the
patient or documented by the clinician. On the other
hand, previous studies have found medical record review
to be fairly accurate compared with other methods of
gathering information [27]. In addition, if a current or
recent relationship with a primary care provider was not
documented on the initial history and physical form, we
counted them as not having an established health care
provider. Thus, we may have underestimated the number
of patients with previously established primary care.
The small sample size and relatively small number of
diagnoses are further limitations. Another limitation is
that there was no comparison group; it is possible that
these problems may have been identified and these sub-
jects may have received treatment even if they had not
initiated treatment or had sought treatment in another
setting. Finally, we did not investigate clinical outcomes
of these patients. There are almost certainly ways in
which their general medical care could be improved fur-
ther; for example, it is notable that few of the subjects
received treatment for hepatitis C infection.
In summary, we found that initiation of office-based
buprenorphine treatment in a primary care setting is
associated with identification and treatment of other
chronic medical problems, suggesting a benefit beyond
drug treatment outcomes.
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